WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection ...
A live webcast of the presentation can be accessed on the investor relations section of the Intensity Therapeutics website. A replay of the webcast will be archived and available following the event ...
INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology ...
A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patient receives two doses of INT230-6 eight days apart, followed by the standard of ...
) has been revised to $57.29 / share. This is a decrease of 11.32% from the prior estimate of $64.60 dated March 25, 2026. The price target is an average of many targets provided by analysts. The ...
Intensity Therapeutics Inc. (NASDAQ:INTS) shares are trending on Friday. Check out the current price of INTS stock here. Shares of the biotechnology company rallied 394.9% in Thursday's regular ...
(RTTNews) - Intensity Therapeutics, Inc. (INTS), a clinical-stage biotechnology company said on Tuesday that it has appointed Joseph Talamo as Chief Financial Officer. He will replace the interim CFO ...
Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard of care ("SOC") compared to SOC alone in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results